FDA approved dostarlimab for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient, as determined by an FDA-authorized test for solid tumors.
FDA approved nogapendekin alfa inbakicept-pmln with Bacillus Calmette-Guérin for adults with BCG-unresponsive non-muscle invasive bladder cancer . This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors to include patients with high-grade papillary-only tumors.
NCT03881488 · Locally Advanced Solid Tumor · Metastatic Cancer · Non-small Cell Lung Cancer · Small Cell Lung Cancer · Mesothelioma · Melanoma · Head and Neck Cancer · PHASE1
Found by registry condition search · Source-reported results, not necessarily final
FDA approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
FDA approved tucatinib in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
FDA approved pirtobrutinib for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.
NCT03082534 · HNSCC · Lip SCC · Oral Cavity Cancer · Oropharynx Cancer · Larynx Cancer · Hypopharynx Cancer · Nasopharynx Cancer · Sinonasal Carcinoma · Cutaneous Squamous Cell Carcinoma · Head and Neck Neoplasms · Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · PHASE2
Found by registry condition search · Source-reported results, not necessarily final
Search stays in your browser. A newer date does not mean stronger evidence or a better treatment.
About this research feed
Papers are citations captured from NCI source reading, not a comprehensive literature search. Titles and bibliographic metadata are preserved; abstracts and full texts are not included. Corrections, retractions and concerns present in the snapshot are flagged; missing flags do not establish that a paper is unaffected.
Trial entries use the date results were first posted, not the date a registry record was last updated. Dates marked estimated by the source stay explicitly labelled. An administrative update is not presented as new findings. Cited trials and condition-search discoveries are labelled separately; this is not a representative sample of all trials.
Papers use the supplied online-publication date when available, otherwise the supplied publication date. Partial dates stay partial and sort after precisely dated entries in the same month or year. An FDA notice is not confirmation of current approved use or a treatment recommendation. Safety notices are distinct from approvals.
0 records without a usable event date and 0 with dates after the release cutoff are not placed in the dated feed. The original records remain in the source library.